Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 20/20 | 1.00 |
| ▸ | ITGB7 | P26010 | 20/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028728 | 0.91 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL6028725 | 0.91 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL8280388 | 0.89 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945967 | 0.88 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945278 | 0.86 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945280 | 0.86 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945274 | 0.84 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945853 | 0.83 | ITGA4 (0.85) | ITGA4ITGB7ITGB1 | |
| SCHEMBL8280368 | 0.82 | ITGA4 (1.00) | ITGA4ITGB7ITGB1 | |
| SCHEMBL24945286 | 0.82 | ITGA4 (0.87) | ITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196342-A1 | α4β1/7 INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | ITGA4 17/4885ITGB7 20/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.